Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Amgen
(NQ:
AMGN
)
263.38
+2.19 (+0.84%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Amgen
< Previous
1
2
...
14
15
16
17
18
19
20
21
22
...
48
49
Next >
2 Dividend Growth Stocks to Buy Right Now
September 21, 2023
A wise man once said, be greedy when others are fearful.
Via
The Motley Fool
Check Out What Whales Are Doing With AMGN
September 20, 2023
Via
Benzinga
Flee to Healthcare Stocks if Recession Rears its Head?
September 20, 2023
In uncertain economic conditions, healthcare stocks can be a refuge due to steady demand and favorable inflation conditions. Many also offer dividends.
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
Amgen Unusual Options Activity
September 15, 2023
Via
Benzinga
3 Quality Dividend Stocks For A Bear Market
September 14, 2023
The potential for a recession means investors should focus on quality dividend stocks with strong yields.
Via
Talk Markets
Topics
Economy
Exposures
Economy
$1000 Invested In This Stock 15 Years Ago Would Be Worth $4,200 Today
September 13, 2023
Via
Benzinga
2 Top Dividend Stocks to Buy in September
September 13, 2023
These two blue-chip dividend stocks have stood the test of time.
Via
The Motley Fool
How Is The Market Feeling About Amgen?
September 08, 2023
Via
Benzinga
8 Analysts Have This to Say About Amgen
September 05, 2023
Via
Benzinga
These 3 Health Care Stocks With Over 3% Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts
September 13, 2023
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Via
Benzinga
The 3 Most Undervalued Biotech Stocks to Buy in September 2023
September 12, 2023
While these undervalued biotech stocks have struggled of late, they could surprise investors and prove to be long-term winners.
Via
InvestorPlace
Another Arthritis Blockbuster Drug Faces Generic Competition: Novartis' Sandoz Inks Pact With Samsung Bioepis
September 11, 2023
Sandoz, a generic and biosimilar medicines unit of Novartis AG (NYSE: NVS), has
Via
Benzinga
Longeveron (NASDAQ: LGVN) Reports 100% 5-Year Survival In Trial For Rare Pediatric Disease HLHS (Compared To 80% Survival In Historical Trials) To Market
September 11, 2023
Advancements in healthcare and medicine have helped contribute to the reduction in child mortality rates, plummeting from 185 per 1,000 births a century ago to just 7 per 1,000 births in 2020. However,...
Via
Benzinga
3 Growth Stocks to Buy in September
September 06, 2023
As the calendar turns to September, optimistic investors will look for value in quality companies with a history of generating strong revenue and earnings
Via
MarketBeat
Topics
Economy
Exposures
Economy
$1000 Invested In This Stock 15 Years Ago Would Be Worth $4,200 Today
August 31, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
September 06, 2023
Via
Benzinga
Amgen's Horizon Acquisition Offers Multiple Advantages: Tax Breaks, Shield From Drug Pricing Negotiations
September 05, 2023
On Friday, the U.S.
Via
Benzinga
Should You Still Buy the Dow Jones' Best-Performing August Stocks?
September 05, 2023
They're rolling now, but this market has been too hot-and-cold of late to ignore any company's -- or company's stock's -- underlying bigger picture.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
The 3 Most Promising Dow Stocks to Own Now
September 03, 2023
The Dow market leaders got their heads handed to them in August. Here are three must-own Dow stocks to own for the long haul.
Via
InvestorPlace
Topics
Stocks
Exposures
US Equities
8 Pharma Stocks Affected by New Drug Price Negotiation Rules
September 02, 2023
Which companies have the most to lose now that Medicare can negotiate directly with them on the prices of some of the most widely used drugs?
Via
The Motley Fool
Stock Market Rally Gains Momentum As Treasury Yields Slide; Tesla Unveils Model 3 Upgrade: Weekly Review
September 01, 2023
Tesla unveiled an updated Model 3, but also slashed Model S, X prices.
Via
Investor's Business Daily
Amgen-Horizon Therapeutics $28B Acquisition: Federal Trade Commission Gives Green Signal
September 01, 2023
The U.S. Federal Trade Commission (FTC) has approved drug manufacturer Amgen Inc (NASDAQ: AMGN) to proceed with its $27.8 billion acquisition of Horizon Therapeutics Plc (NASDAQ: HZNP).
Via
Benzinga
Amgen, Horizon Therapeutics Stocks Jump After FTC Clears Their $28 Billion Marriage
September 01, 2023
The deal can now close in the fourth quarter.
Via
Investor's Business Daily
Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition
September 01, 2023
From
Horizon Therapeutics plc and Amgen
Via
Business Wire
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?
September 01, 2023
Pharmaceutical stocks are holding steady as Medicare price negotiations approach, but industry diversification and innovation support future growth prospects.
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
Is This the Green Light Biotech Stocks Have Been Waiting For?
August 31, 2023
It looks like the Federal Trade Commission will give up on its attempt to block Amgen's acquisition of Horizon Therapeutics.
Via
The Motley Fool
What Impact Will Medicare Price Negotiations Have on Big Pharma Stocks?
August 29, 2023
Investors appear to be yawning for the most part at the latest news on Medicare drug price negotiations.
Via
The Motley Fool
Important Data Ahead, Tesla Turning On Massive Nvidia Cluster, 10 Drugs Name For Price Cuts
August 29, 2023
To gain an edge, this is what you need to know today.
Via
Benzinga
Biden Targets Cancer, Diabetes Drugs In Controversial Medicare Price Battle
August 29, 2023
The Centers for Medicare and Medicaid Services unveiled the first ten drugs subject to price negotiations under President Joe Biden's Inflation Reduction Act, including:
Via
Benzinga
Blockbusters From AbbVie, Merck, Lilly Highlight List Of 10 Drugs Subject To Price Cuts
August 29, 2023
The Biden administration is planning to negotiate the prices of 10 drugs in 2026.
Via
Investor's Business Daily
< Previous
1
2
...
14
15
16
17
18
19
20
21
22
...
48
49
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.